Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBITDA Margin: 2020-2025

Historic EBITDA Margin for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -6.38%.

  • GeneDx Holdings' EBITDA Margin rose 384.00% to -6.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.54%, marking a year-over-year increase of 3144.00%. This contributed to the annual value of -16.99% for FY2024, which is 6958.00% up from last year.
  • Per GeneDx Holdings' latest filing, its EBITDA Margin stood at -6.38% for Q3 2025, which was down 161.11% from 10.44% recorded in Q2 2025.
  • GeneDx Holdings' 5-year EBITDA Margin high stood at 75.80% for Q3 2021, and its period low was -503.28% during Q4 2022.
  • Moreover, its 3-year median value for EBITDA Margin was -32.64% (2024), whereas its average is -40.23%.
  • Per our database at Business Quant, GeneDx Holdings' EBITDA Margin slumped by 43,375bps in 2022 and then skyrocketed by 45,913bps in 2023.
  • Quarterly analysis of 5 years shows GeneDx Holdings' EBITDA Margin stood at -69.52% in 2021, then crashed by 43,375bps to -503.28% in 2022, then skyrocketed by 45,913bps to -44.15% in 2023, then skyrocketed by 4,974bps to 5.59% in 2024, then skyrocketed by 384bps to -6.38% in 2025.
  • Its last three reported values are -6.38% in Q3 2025, 10.44% for Q2 2025, and -7.41% during Q1 2025.